Nordic Nanovector to present at 11th Annual World ADC Europe 2021 Digital
Oslo, March 8, 2021 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) announces that its Chief Scientific Officer, Jostein Dahle, will give a presentation on 9 March at the 11th Annual World ADC Europe 2021 Digital event (8-11 March 2021) in the Discovery stream discussing the question: Should Payloads be Super-Potent?
Presentation details are as follows:
Title: Targeting CD37 with Alpha- & Beta-Emitting Radioimmunoconjugates
Date/time: Tuesday, 9 March 2021 at 11:40am GMT
During his presentation, Dr Dahle with cover the following points:
Review CD37 as target for radioimmunotherapy
Analyse preclinical and clinical data for treatment of Non-Hodgkin's Lymphoma (NHL) with the beta-emitting radioimmunoconjugate 177Lu-lilotomab satetraxetan (Betalutin®)
Evaluate preclinical data for treatment of Chronic Lymphocytic Leukaemia and NHL with the alpha-emitting radioimmunoconjugate 212Pb-TCMC-NNV003 (Alpha37)
World ADC Europe is an industry-leading conference and Europe's largest gathering of ADC stakeholders. It brings together 300 drug developers from 160 active ADC organisations to help forward-thinking researchers from the pharmaceutical, biotech and academic community advance the development of antibody-drug conjugates.
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 26 billion by 2028. Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets.
Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, presented data on its X-Editor (XE) and Epigenetic Long-Term X-Repressor (ELXR) technologies at the 27th American Society of...
Vibrant Wellness, a CLIA-certified and CAP-accredited biotechnology company based in Santa Clara, CA, proudly announced their expansion in the UK.Vibrant is known for their extensive selection of specialty precision lab testing. The company combines...
In recent years, saunas have become the hottest trend for more reasons than one. It is not just about relaxing or loosening up those muscles anymore - sauna and heat therapy provide many benefits.
Kutting Weight sauna suit clothing has been...
Mary Dickinson, Ph.D., an internationally recognized geneticist, developmental biologist and bioengineer who has pioneered the understanding of human disease through advanced imaging technology, has joined The Jackson Laboratory (JAX)...
Ossium Health, an innovative bioengineering company that established a first-of-its-kind bone marrow bank, announced today the launch of a new program that further expands patient access to Ossium's bone marrow. Through the HOPE (HPC Offered for...
Grossman Law Offices, with its principal office in Dallas, TX, extends its thoughts and support to John Hidalgo following a truck accident that occurred on April 14, 2024, around 3:50 p.m. along U.S. Highway 281 in San Antonio, TX. Mr. Hidalgo...